Manuel Wallbach1, Ellen Born2, Deborah Kämpfer2, Stephan Lüders3, Gerhard A Müller2, Rolf Wachter4,5, Michael J Koziolek2. 1. Department of Nephrology and Rheumatology, University Medical Center Göttingen, Robert-Koch-Str. 40, 37075, Göttingen, Germany. manuel.wallbach@med.uni-goettingen.de. 2. Department of Nephrology and Rheumatology, University Medical Center Göttingen, Robert-Koch-Str. 40, 37075, Göttingen, Germany. 3. St. Josefs Hospital, Cloppenburg, Germany. 4. Department of Cardiology and Pulmonology, University Medical Center Göttingen, Göttingen, Germany. 5. Clinic and Policlinic for Cardiology, University Hospital Leipzig, Leipzig, Germany.
Abstract
OBJECTIVE: Baroreflex activation therapy (BAT) reduces office blood pressure (BP) in patients with resistant hypertension (HTN). Whereas sustained effects from the BAT Rheos device have already been reported, no long-term data on 24-h ambulatory BP (ABP) are currently available for the unilateral BAT Neo device. METHODS: Patients treated with the BAT neo device for resistant hypertension were prospectively included into this observational study. Office and ABP measurements were performed before BAT implantation as well as 6, 12 and 24 months after initiation of BAT. RESULTS: A total of 60 patients with resistant HTN (office BP 172 ± 25/90 ± 17 mmHg, 24-h ABP 150 ± 16/80 ± 12 mmHg, median of antihypertensive drugs 7 (IQR 6-8)) were included. After 24 months, there was a significant reduction of - 25 ± 33/- 9 ± 18 mmHg (n = 50, both p < 0.01) in office BP and - 8 ± 23/- 5 ± 13 mmHg (n = 46, both p = 0.02) in 24-h ABP, while the number of antihypertensive medications was reduced to a median of 5 (4-6) drugs (p < 0.01). Patients with isolated systolic HTN (ISH) experienced a BP-lowering effect in office BP, but not in ABPM at month 24. Using unadjusted BP values, BAT seems to be more effective in combined hypertension (CH) than in ISH. After adjustment for baseline BP values, there was no significant difference in BP reduction between ISH and CH patients. Ambulatory SBP at baseline was the only independent correlate of BP response at month 24. CONCLUSION: BAT reduced office BP and improved relevant parameters of ABP, which is associated with a high cardiovascular risk, in patients with resistant HTN, whereas, after adjustment for baseline BP, BP reduction was not different in patients with CH compared with patients with ISH. However, randomized controlled trials are needed to confirm the effects of BAT on 24-h ABP.
OBJECTIVE: Baroreflex activation therapy (BAT) reduces office blood pressure (BP) in patients with resistant hypertension (HTN). Whereas sustained effects from the BAT Rheos device have already been reported, no long-term data on 24-h ambulatory BP (ABP) are currently available for the unilateral BAT Neo device. METHODS:Patients treated with the BAT neo device for resistant hypertension were prospectively included into this observational study. Office and ABP measurements were performed before BAT implantation as well as 6, 12 and 24 months after initiation of BAT. RESULTS: A total of 60 patients with resistant HTN (office BP 172 ± 25/90 ± 17 mmHg, 24-h ABP 150 ± 16/80 ± 12 mmHg, median of antihypertensive drugs 7 (IQR 6-8)) were included. After 24 months, there was a significant reduction of - 25 ± 33/- 9 ± 18 mmHg (n = 50, both p < 0.01) in office BP and - 8 ± 23/- 5 ± 13 mmHg (n = 46, both p = 0.02) in 24-h ABP, while the number of antihypertensive medications was reduced to a median of 5 (4-6) drugs (p < 0.01). Patients with isolated systolic HTN (ISH) experienced a BP-lowering effect in office BP, but not in ABPM at month 24. Using unadjusted BP values, BAT seems to be more effective in combined hypertension (CH) than in ISH. After adjustment for baseline BP values, there was no significant difference in BP reduction between ISH and CH patients. Ambulatory SBP at baseline was the only independent correlate of BP response at month 24. CONCLUSION: BAT reduced office BP and improved relevant parameters of ABP, which is associated with a high cardiovascular risk, in patients with resistant HTN, whereas, after adjustment for baseline BP, BP reduction was not different in patients with CH compared with patients with ISH. However, randomized controlled trials are needed to confirm the effects of BAT on 24-h ABP.
Authors: Eoin O'Brien; Gianfranco Parati; George Stergiou; Roland Asmar; Laurie Beilin; Grzegorz Bilo; Denis Clement; Alejandro de la Sierra; Peter de Leeuw; Eamon Dolan; Robert Fagard; John Graves; Geoffrey A Head; Yutaka Imai; Kazuomi Kario; Empar Lurbe; Jean-Michel Mallion; Giuseppe Mancia; Thomas Mengden; Martin Myers; Gbenga Ogedegbe; Takayoshi Ohkubo; Stefano Omboni; Paolo Palatini; Josep Redon; Luis M Ruilope; Andrew Shennan; Jan A Staessen; Gert vanMontfrans; Paolo Verdecchia; Bernard Waeber; Jiguang Wang; Alberto Zanchetti; Yuqing Zhang Journal: J Hypertens Date: 2013-09 Impact factor: 4.844
Authors: John D Bisognano; George Bakris; Mitra K Nadim; Luis Sanchez; Abraham A Kroon; Jill Schafer; Peter W de Leeuw; Domenic A Sica Journal: J Am Coll Cardiol Date: 2011-08-09 Impact factor: 24.094
Authors: Rolf Wachter; Marcel Halbach; George L Bakris; John D Bisognano; Hermann Haller; Joachim Beige; Abraham A Kroon; Mitra K Nadim; Eric G Lovett; Jill E Schafer; Peter W de Leeuw Journal: J Am Soc Hypertens Date: 2016-12-16
Authors: Annemiek F Hoogerwaard; Ahmet Adiyaman; Mark R de Jong; Jaap Jan J Smit; Peter Paul H M Delnoy; Jan-Evert Heeg; Boudewijn A A M van Hasselt; Anand R Ramdat Misier; Michiel Rienstra; Arif Elvan Journal: Clin Res Cardiol Date: 2018-05-29 Impact factor: 5.460
Authors: Oliver Jung; Janis L Gechter; Cora Wunder; Alexander Paulke; Christine Bartel; Helmut Geiger; Stefan W Toennes Journal: J Hypertens Date: 2013-04 Impact factor: 4.844
Authors: Karl Fengler; Karl-Philipp Rommel; Razvan Lapusca; Stephan Blazek; Christian Besler; Philipp Hartung; Maximilian von Roeder; Karl-Patrik Kresoja; Steffen Desch; Holger Thiele; Philipp Lurz Journal: Hypertension Date: 2019-06-17 Impact factor: 10.190
Authors: Felix Mahfoud; George Bakris; Deepak L Bhatt; Murray Esler; Sebastian Ewen; Martin Fahy; David Kandzari; Kazuomi Kario; Giuseppe Mancia; Michael Weber; Michael Böhm Journal: Eur Heart J Date: 2017-01-07 Impact factor: 29.983
Authors: Lukas Stoiber; Felix Mahfoud; Seyedeh Mahsa Zamani; Tomas Lapinskas; Michael Böhm; Sebastian Ewen; Saarraaken Kulenthiran; Markus P Schlaich; Murray D Esler; Tommy Hammer; Knut Haakon Stensæth; Burkert Pieske; Stephan Dreysse; Eckart Fleck; Titus Kühne; Marcus Kelm; Philipp Stawowy; Sebastian Kelle Journal: Clin Res Cardiol Date: 2018-03-08 Impact factor: 5.460
Authors: C Tsioufis; A Ziakas; K Dimitriadis; P Davlouros; M Marketou; A Kasiakogias; C Thomopoulos; D Petroglou; D Tsiachris; M Doumas; E Skalidis; C Karvounis; D Alexopoulos; P Vardas; I Kallikazaros; C Stefanadis; V Papademetriou; D Tousoulis Journal: Clin Res Cardiol Date: 2016-12-12 Impact factor: 5.460